BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia, arises in a primitive hematopoietic stem cell that has the capacity for both differentiation and self-renewal. Its product, Bcr-Abl protein, has been shown to activate signal transducers and activators of transcription 3 (STAT3) and to promote self-renewal in embryonic stem (ES) cells, even in the absence of leukemia inhibitory factor (LIF). MEK kinase 1 (MEKK1) is a 196-kDa mitogen-activated protein kinase (MAPK) kinase kinase involved in Bcr-Abl signal transduction. To investigate the role of MEKK1 in Bcr-Abl-induced transformation of stem cells, p210 Bcr-Abl was stably transfected into wildtype (WT p210 ) and MEKK1À/À (MEKK1À/À p210 ) ES cells. Bcr-Abl enhanced MEKK1 expression in ES transfectants, as it does in other Bcr-Abl-transformed cells. In the absence of LIF, WT p210 cells showed constitutive STAT3 activation and formed rounded, compact colonies having strong alkaline phosphatase activity, a characteristic phenotype of undifferentiated ES cells. MEKK1À/À p210 cells, by contrast, showed less STAT3 activity than WT p210 cells and formed large, flattened colonies having weak alkaline phosphatase activity, a phenotype of differentiated ES cells. These results indicate that MEKK1 plays a key role in Bcr-Ablinduced STAT3 activation and in ES cells' capacity for LIF-independent self-renewal, and may thus be involved in Bcr-Abl-mediated leukemogenesis in stem cells.
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Introduction
Chronic myelogenous leukemia (CML) is a neoplasm arising from primitive hematopoietic cells expressing the 210-kDa form of Bcr-Abl, a chimeric oncoprotein generated by the reciprocal translocation t(9;22) (Deininger et al., 2000) . This oncoprotein is responsible for the phosphorylation, activation and dysregulation of various intracellular signaling proteins that regulate the proliferation and survival of progenitor cells. Patients with CML have a rare but consistently detectable population of quiescent Bcr-Abl-positive CD34 þ cells (Holyoake et al., 1999 ) that possess an ability for selfrenewal and contribute to the disease's pathogenesis. One recent study showed that Bcr-Abl constitutively activates signal transducers and activators of transcription 3 (STAT3) and promotes self-renewal of embryonic stem (ES) cells, even in the absence of leukemia inhibitory factor (LIF). Similarly, CD34 þ cells purified from CML patients show increased levels of STAT3 activation (Coppo et al., 2003) .
MEK kinase 1 (MEKK1) is a 196-kDa mitogenactivated protein kinase (MAPK) kinase kinase that is activated in response to a variety of stimuli, and has been shown to participate in the regulation of c-Jun Nterminal kinase (JNK) and extracellular signal regulated kinase (ERK) activity, and to be involved in the activation of NF-kB (Hagemann and Blank, 2001 ). In addition, we previously showed that cell transformation induced by Bcr-Abl leads to increased expression of MEKK1, which then serves as a downstream target of Bcr-Abl, mediating an antiapoptotic effect (Nawata et al., 2003) . To investigate the role of MEKK1 in BcrAbl-induced transformation of stem cells, we used a stable line of p210 Bcr-Abl-transfected MEKK1À/À ES cells to examine the effects of disrupting MEKK1 expression on the Bcr-Abl-induced undifferentiated phenotype and constitutive STAT3 activation. Our findings show for the first time that the MEKK1-STAT3 pathway is a downstream target of Bcr-Abl that mediates maintenance of the undifferentiated phenotype of ES cells.
Results

Bcr-Abl increases MEKK1 expression in ES cells
We began investigating the relationship between Bcr-Abl and MEKK1 by evaluating MEKK1 expression in p210 Bcr-Abl-transformed ES cells. We found that expression of MEKK1 protein was constitutively increased in Bcr-Abl-transformed wild-type (WT Figure 1a) .
To investigate the relationship between Bcr-Abl activity and MEKK1 expression in more detail, we next examined the effects of imatinib mesylate (STI571), a selective inhibitor of Bcr-Abl tyrosine kinase activity (Druker, 2002 (Figure 2a) . To confirm the differentiation status of cells, we measured alkaline phosphatase activity (Pease et al., 1990) and found that, whereas about 67% of WT p210 cells were alkaline phosphatase-positive in the absence of LIF, MEKK1À/À p210 cells were almost all alkaline phosphatase-negative (Figure 2b and c) . This suggests that BcrAbl confers the ability to maintain an undifferentiated state in the absence of LIF, and that this effect is mediated by MEKK1. 
MEKK1 is essential for Bcr-Abl-induced STAT3 activation
LIF-induced STAT3 activation is essential for maintaining an undifferentiated state in ES cells (Burdon et al., 2002) , although one recent study showed that Bcr-Abl constitutively activates STAT3, thereby promoting self-renewal in ES cells even in the absence of LIF (Coppo et al., 2003) . We therefore investigated the extent to which MEKK1 is involved in Bcr-Abl-induced STAT3 activation. Using immunoblot analyses, we found that, in the absence of LIF, STAT3 was more strongly phosphorylated on both Tyr705 and Ser727 in WT p210 cells than in WT GFP cells, and that the increased phosphorylation was associated with an increase in the level of total STAT3 protein. By contrast, the level of phosphorylated STAT3 in MEKK1À/À p210 cells was similar to that in MEKK1À/À GFP cells (Figure 3a-d) , which suggests that MEKK1 is required for Bcr-Ablinduced STAT3 expression and phosphorylation. Evaluation of Bcr-Abl-induced STAT3 mRNA expression using semiquantitative RT-PCR analysis showed cells, but not in WT GFP cells (Figure 3f ), suggesting that Bcr-Abl tyrosine kinase activity contributes to both the expression and phosphorylation of STAT3 in the absence of LIF.
We used electrophoretic mobility shift assays (EMSAs) to evaluate the binding of STAT3 to DNA in the nucleus. In the absence of LIF, higher levels of STAT3 binding to DNA were detected in WT p210 than WT GFP cells, though no difference was detected between MEKK1À/À GFP and MEKK1À/À p210 cells (Figure 4a ). That STAT3 was bound to its physiological binding site is suggested by our finding that formation of the STAT3-DNA complex was competitively inhibited in the presence of an excess of unlabeled SIEm67 (data not shown). Additional evidence that Bcr-Abl induces nuclear translocation of both total and phosphorylated STAT3 via MEKK1 was obtained when nuclear and cytoplasmic lysates were immunoblotted with anti-STAT3 and anti-phospho-STAT3 (Tyr705). The results showed that nuclear levels of phospho-STAT3 paralleled those of total STAT3 (Figure 4b ) and were correlated with STAT3-DNA-binding activity. The physiological nature of the STAT3 binding was further substantiated by luciferase assays, which showed that the transcriptional activity of STAT3 in the absence of LIF was consistent with the results of both the immunoblot analyses and EMSAs (Figure 4c ). Furthermore, reconstitution of MEKK1À/À ES cells by transfecting them with WT MEKK1 (MEKK1 addback) restored the ability of Bcr-Abl to activate STAT3 (Figure 4d ), confirming that MEKK1 is required for Bcr-Abl-induced STAT3 activation.
Bcr-Abl-induced MEKK1-STAT3 pathway is not involved with ERK, JNK, JAK2 or Rac1
Bearing in mind that MEKK1 is a physiological regulator of JNK and ERK (Yujiri et al., 1998) , we next investigated which intracellular signaling protein(s) is involved in the Bcr-Abl-MEKK1-STAT3 pathway. Immunoblot analyses using phosphospecific Abs showed that Bcr-Abl enhanced ERK activation in both WT p210 and MEKK1À/À p210 cells in the absence of LIF. On the other hand, JNK activation was not elevated in either cell type (Figure 5a) , and MEKK1À/À GFP and MEKK1À/À p210 cells, respectively, showed less ERK activity than WT GFP and WT p210 cells (Figure 5a ). Treating WT p210 cells with the MEK1/2 inhibitor U0126 completely blocked ERK activity, reducing phosphorylation of STAT3 on Ser727 but not on Tyr705; STAT3 binding to DNA was unaffected (Figure 5b ). Although ERK activity has been linked to STAT3 Ser727 phosphorylation and to the negative regulation of STAT3 activity (Decker and Kovarik, 2000) , our result indicates that Bcr-Abl-induced ERK activation does not contribute to the STAT3 activation seen in the absence of LIF. In addition, the reduced ERK activity seen in MEKK1À/À p210 cells did not cause a decrease in STAT3 activation.
Janus kinase 2 (JAK2) is also a physiological regulator of STAT3 activation (Hirano et al., 2000) , but we found that tyrosine phosphorylation of JAK2 - and thus its activation -was unaffected by Bcr-Abl (Figure 6a) .
Finally, we assessed the activity of the small GTPase Rac1 because it reportedly regulates epidermal growth factor (EGF)-mediated STAT3 activation (Simon et al., 2000) and is activated by Bcr-Abl (Skorski et al., 1998) , and because MEKK1 reportedly associates with GTPbound active Rac1 (Fanger et al., 1997) . We found that levels of GTP-bound Rac1 were not increased by BcrAbl in ES cells (Figure 6b) . Collectively, therefore, our findings suggest that Bcr-Abl activates an MEKK1-STAT3 pathway, though not through ERK, JNK, JAK2 or Rac1.
Discussion
During the chronic phase of CML, Bcr-Abl-expressing leukemic stem cells are characterized by their persistent ability to differentiate towards all hematopoietic lineages. The signaling pathway by which the Bcr-Ablexpressing clone expands and undergoes self-renewal remains largely unknown, however. We therefore used murine undifferentiated ES cells to investigate the early molecular events that occur in Bcr-Abl-associated leukemogenesis. As reported previously (Coppo et al., 2003) , Bcr-Abl-expressing ES cells persistently exhibited a primitive morphology, despite LIF withdrawal. In addition, like Bcr-Abl-transformed 32D and Ba/F3 cells (Nawata et al., 2003) , they showed enhanced MEKK1 expression and activation.
To define the significance of MEKK1 activation in Bcr-Abl-induced leukemogenesis, we compared Bcr-Abl-induced transformation of WT and MEKK1-deficient ES cells. Surprisingly, the ability of Bcr-Abl, in the absence of LIF, to induce changes in both the morphology of ES cell colonies and alkaline phosphatase activity that were consistent with an undifferentiated phenotype was MEKK1-dependent, suggesting that MEKK1 plays a key role in Bcr-Abl-induced Figure 5 Bcr-Abl-induced STAT3 activation is not via ERK or JNK. (a) In the absence of LIF, ES cell lysates were immunoblotted for ERK2, phospho-ERK, JNK1 and phospho-JNK. Levels of GAPDH confirmed that equivalent amounts of protein had been loaded into each lane. (b) In the absence of LIF, Bcr-Abltransformed WT ES cells were treated with 10 mM U0126 for the indicated times, after which whole-cell lysates were immunoblotted for STAT3 and phospho-STAT3 (Tyr705 and Ser727), and nuclear extracts were subjected to EMSA using SIEm67 as a probe. The data shown are representative of three independent experiments yielding similar results Figure 6 Bcr-Abl-induced STAT3 activation is not via JAK2 or Rac1. (a) In the absence of LIF, ES cell lysates were immunoprecipitated for JAK2 and immunoblotted with 4G10 and anti-JAK2 Ab. (b) In the absence of LIF, ES cell lysates were harvested, and the amount of GTP-bound Rac1 (GTP-Rac1) was determined using PAK1 pull-down assays. In addition, a portion (1/10) of the cell lysate was subjected to immunoblot analysis to determine the total amount of Rac1 in each sample. The immunoblotting shown is representative of three independent experiments yielding similar results
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Y Nakamura et al self-renewal of ES cells via a Bcr-Abl-mediated transformation pathway. The role of STAT3 activation in the promotion of self-renewal in ES cells is well established; indeed, constitutive activation of STAT3 has been shown not only in Bcr-Abl-expressing ES cells but also in primary CML cells (Coppo et al., 2003) . Nevertheless, it was unexpected that MEKK1 would be required for Bcr-Abl-induced STAT3 activation in ES cells. Our findings with genetically deficient cells enable us to report for the first time that not only is MEKK1 involved in STAT3 activation but also its action is independent of MAPK family pathways. By transfecting cells with MEKK1 cDNA, Lim and Cao (2001) showed that MEKK1 regulates growth factor-induced STAT3 activation and phosphorylation of STAT3 protein on both Tyr705 and Ser727. We found that Bcr-Abl induces constitutive activation of ERK, but not JNK, JAK2 or Rac1, which have been thought to regulate STAT3 activation. In addition, treating cells with an MEK inhibitor showed that the MEKK1-ERK pathway does not contribute to Bcr-Abl-induced STAT3 activation. It is thus plausible that MEKK1 directly regulates the activation of STAT3 in Bcr-Abl-expressing stem cells.
In conclusion, our findings suggest that MEKK1 plays a key role in self-renewal and STAT3 activation in Bcr-Abl-transformed ES cells. Although it remains to be determined precisely how MEKK1 contributes to Bcr-Abl-induced transformation of hematopoietic stem cells, our findings suggest that MEKK1 may be a useful therapeutic target for the treatment of CML.
Materials and methods
Cell culture
WT, MEKK1À/À and MEKK1 add-back CCE ES cells (Yujiri et al., 1998) were maintained on gelatin-coated dishes in DMEM (Invitrogen) supplemented with 25 mM Hepes, 100 U/ml penicillin, 100 mg/ml streptomycin (Invitrogen), 15% fetal bovine serum (Equitech-Bio, Inc.), 0.5% LIF-conditioned medium and 0.14 mM monothioglycerol (Sigma). Bcr-Ablexpressing ES cells were selected by adding 0.8 mg/ml puromycin to the ES cell culture medium. All of these cell lines were used as monoclonal cell mixtures.
Materials
Anti-c-Abl Ab was purchased from Oncogene Research. Anti-MEKK1, -ERK2, -JNK1 and -phospho-JNK Abs were from Santa Cruz Biotechnology. Anti-STAT3, -phospho-STAT3 (Tyr705), -phospho-STAT3 (Ser727) and -phospho-ERK Abs were from Cell Signaling Technology. Anti-JAK2 and -Rac1 Abs were from Upstate Biotechnology. Antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) Ab was from Chemicon. 4G10 antiphosphotyrosine mAb is described elsewhere (Ogihara et al., 1997) . U0126 was from Calbiochem. STI571 was kindly provided by Novartis (Basel, Switzerland). Stock solutions of U0126 (10 mM) and STI571 (10 mM) were prepared in dimethylsulfoxide and stored at À80 and À201C, respectively. Appropriate drug concentrations were made by dilution with fresh medium immediately before each experiment. The retroviral vector pMY was prepared as described previously (Nawata et al., 2003) . p210 Bcr-Abl cDNA was a gift from Dr Owen N Witte (UCLA). WT and MEKK1À/À ES cells were stably transformed with pMY-GFP or pMY-p210-Bcr-Abl. pGEX-2T-PAK was kindly provided by Dr Yoh Takuwa (Kanazawa University).
Immunoblotting and immunoprecipitation
ES cells were lysed as described previously (Nawata et al., 2003) . For immunoprecipitation, the lysates were incubated first with anti-c-Abl or anti-JAK2 Ab for 2 h at 41C and then with protein G-Sepharose (Amersham Biosciences) for an additional 3 h. The Sepharose beads were then washed two times in lysis buffer and resuspended in Laemmli sample buffer. The immunoprecipitates were resolved by SDS-PAGE.
Alkaline phosphatase staining ES cell colonies were fixed and stained for alkaline phosphatase using naphthol/fast red violet solution following the manufacturer's instructions (Chemicon). Numbers of alkaline phosphatase-positive colonies were scored by microscopic examination.
Semiquantitative RT-PCR
Total RNA was extracted from ES cells using ISOGEN (Nippongene, Toyama, Japan) according to the manufacturer's protocol, after which cDNA was synthesized using SuperScript II (Invitrogen) with 1-mg aliquots of total RNA. PCR was then run for 25 cycles, and primer annealing for STAT3 was carried out at 581C for 1 min. The sequences of the PCR primers were: for STAT3, 5 0 -ATG AAG AGT GCC TTC GTG GTG G-3 0 (sense) and 5 0 -GGA TTG ATG CCC AAG CAT TTG G-3 0 (antisense), and for b-actin, 5 0 -ATG TGC AAG GCC GGC TTC GCG GGC GAC G-3 0 (sense) and 5 0 -CAG CCA GGT CCA GAC GCA GGA TGG CAT-3 0 (antisense). Thereafter, 10 ml of each PCR product was electrophoresed on 2.0% agarose gels, and the intensities of the specific bands were determined using NIH Image software. As an internal control, the relative level of STAT3 mRNA was normalized to that of b-actin mRNA.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein extracts were prepared from ES cells as described previously (Nawata et al., 2003) , after which aliquots of the extract were preincubated for 15 min at room temperature with 0.8 mg of poly(dI-dC) in binding buffer (20 mM Tris-HCl (pH 7.5), 50 mM potassium chloride, 5% glycerol, 1 mM dithiothreitol, 1 mM EDTA and 0.1% NP40). A 32 P-labeled DNA probe for the STAT3-binding site SIEm67 (Sadowski et al., 1993) was then added, and the incubation was continued for an additional 15 min. Finally, the DNA-protein complexes were separated on a 6% polyacrylamide gel and exposed for autoradiography.
Luciferase assays
Using FuGENE6 (Roche), ES cells were transiently transfected with 3 mg of pTA-Luc or pSTAT3-TA-Luc vector (Clontech), together with 2 mg of the b-galactosidase reporter vector CH110 (Promega). The negative control (pTA-Luc) lacks the STAT3 enhancer element, but contains a TATA box promoter and luciferase reporter gene. pSTAT3-TA-Luc contains four copies of the STAT3 enhancer element (TGCTTCCCGAACGT). At 24 h after transfection, the cells were lysed with PicaGene reporter lysis buffer (Toyo Inki, Tokyo, Japan), and the luciferase activity in the lysates was measured using a PicaGene luciferase assay kit (Toyo Inki, Tokyo, Japan). To control for variation in transfection efficiency, luciferase activity was normalized to the corresponding b-galactosidase activity. The values obtained from controls (pTA-Luc) were subtracted from experimental results (pSTAT3-TA-Luc).
Measuring GTP-Rac1 levels Levels of activated, GTP-bound Rac1 were measured using PAK1 pull-down assays as described previously (Okamoto et al., 2000) . Briefly, the cells were collected and lysed, after which the lysates were clarified and incubated with GST-PAK1 (amino acids 75-131) on beads to capture GTP-bound Rac1
proteins. The bound proteins were washed three times and eluted with sample buffer before being subjected to SDS-PAGE and immunoblotted with an anti-Rac1 Ab. Whole-cell lysates (10% of input) were analysed in parallel.
